The herbal pharmaceutical company, Himalaya Drug Company, is hopeful of registering a 20 per cent compound annual growth rate (CAGR) for the next three to five years on the back of sound demand for its pharmaceutical drugs.
“Presently, our turnover stands around Rs 1,000 crore per annum, 60 per cent of which comes from pharmaceutical verticals as of now. We are hopeful of registering a 20 per cent CAGR in the next three to five years,” Philipe Haydon, president and chief executive officer of pharmaceuticals, Himalaya Drug Company said here on the sidelines of launching a range of oral care products.
The company, which manufactures a range of ayurvedic products in pharmaceuticals, personal care and animal health, aims to touch a 5 per cent market share for ethical oral care market in its newly-launched segment.
“While the personal oral care market in India is worth around Rs 4,400 crore, it stands at Rs 250 crore in the ethical oral care segment,” he said. Presently, overseas markets like West Asia, US, Russia and Singapore contribute around 40 per cent of the total turnover of the company.
“Barring foreign markets, the company is also betting big on the domestic market by expansion in the rural market and through retail operation and government tenders,” Haydon added.
He also said the com-pany, which has around 120 retail stores, was planning to open two every month in the country.
“We are also working with governments of Bihar, Madhya Pradesh and Gujarat to supply drugs to government agencies,” he added.
The nearly zero debt company, however, doesn’t have any plans to raise money either to fund its R&D expenditure or for future expansion.
Referring to manufacturing ability of the company, he said that the company’s present manufacturing capacity was enough to meet the rising demand and it had also a tie-up with around 40 vendors in this space.
The company has around 83 patent filings before various authorities and it has already received seven approvals, he added.
Talking about any drug pipeline, he said that the company has around 40 drugs under various stages of trials.
The company is also planning to launch a new prescription drug for liver in the coming months, Haydon added.
